2-amino-5-(4-methylpiperidinyl)benzamide | 314768-98-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-amino-5-(4-methylpiperidinyl)benzamide
• 英文别名: 2-amino-5-(4-methylpiperidin-1-yl)benzamide
• CAS: 314768-98-4
• 化学式: C₁₃H₁₉N₃O
• 分子量: 233.313
• InChiKey: KAAJPGPDKJDBDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  72.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-甲氧基苯甲醛 、 2-amino-5-(4-methylpiperidinyl)benzamide 以57.6%的产率得到2-(3-methoxyphenyl)-6-(4-methyl-1-piperidyl)-3H-quinazolin-4-one
  参考文献：
  名称：

  2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions

  摘要：

  合成了两种系列的化合物，分别是6,7,2′,3′,4′,5′-取代的2-苯基-4-喹唑啉酮和6,2′,3′,4′,5′-取代的2,3-二氢-2-苯基-4-喹唑啉酮，并评价了它们对人肿瘤细胞系如鼻咽癌上皮细胞癌（KB）、肺癌（A-549）、回肠癌（HCT-8）、乳腺癌（MCF-7）、黑色素瘤（SKMEL-2）、卵巢癌（1A9）、胶质母细胞瘤（U-87-MG）、骨肉瘤（HOS）、表达P-gp的鼻咽癌上皮细胞癌（KB-VIN）和前列腺癌（PC3）细胞系的细胞毒性，发现其中一些化合物具有显著的活性。本发明还合成了2-苯基-4-烷氧基喹唑啉化合物，其中一些化合物显示出抗血小板活性。

  公开号：

  US06479499B1
• 作为产物：
  描述：

  5-氯-2-硝基苯甲酸 在 10percent Pd/C 氯化亚砜 、 氨 、 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 13.0h， 生成 2-amino-5-(4-methylpiperidinyl)benzamide
  参考文献：
  名称：

  6-Alkylamino- and 2,3-Dihydro-3‘-methoxy-2-phenyl-4-quinazolinones and Related Compounds:  Their Synthesis, Cytotoxicity, and Inhibition of Tubulin Polymerization

  摘要：

  As part of our continuing search for potential anticancer candidates among 2-phenyl-4-quinolones and 2-phenyl-4-quinazolinones, two series of 6,7,2',3',4',5'-substituted 2-phenyl-4-quinazolinones and 6,2',3',4',5'-substituted 2,3-dihydro-2-phenyl-4-quinazolinones were synthesized and evaluated for cytotoxicity and as inhibitors of tubulin polymerization. In general, a good correlation was found between the two activities. Five of the 6-substituted heterocyclic 2-phenyl-4-quinozolinones (37-51) showed significant cytotoxicity against a panel of human tumor cell lines with EC50 values in the low micromolar to nanomolar concentration ranges. Compound 38 was the most potent of these compounds, as well as the most potent inhibitor of tubulin polymerization in this series. The activity of 38 was in the same range as those of the antimitotic natural products, colchicine, podophyllotoxin, and combretastatin A-4. Substituted 2-phenyl-4-quinazolinones and 2,3-dihydro-2-phenyl-4-quinazolinones also displayed highly selective cytotoxicity against the ovarian cancer 1A9 and P-gp resistant KB-VIN cell lines.

  DOI：

  10.1021/jm000151c

文献信息

• 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions
  申请人：National Science Council

  公开号：US06479499B1

  公开（公告）日：2002-11-12

  Two series of 6,7,2′,3′,4′,5′-substituted 2-phenyl-4-quinazolinones and 6,2′,3′,4′,5′-substituted 2,3-dihydro-2-phenyl-4-quinazolinones are synthesized and evaluated for cytotoxicity against a panel of human tumor cell lines, such as epidermoid carcinoma of the nasopharynx (KB), lung carcinoma (A-549), ileocecal carcinoma (HCT-8), breast cancer (MCF-7), melanoma (SKMEL-2), ovarian cancer (1A9), glioblastoma (U-87-MG), bone (HOS), P-gp-expressing epidermoid carcinoma of the nasopharynx (KB-VIN), and prostate cancer (PC3) cell lines, and some of the compounds are found potent. The present invention also synthesizes 2-phenyl-4-alkoxy-quinazoline compounds, wherein some of the compounds exhibit antiplatelet activity.

  合成了两种系列的化合物，分别是6,7,2′,3′,4′,5′-取代的2-苯基-4-喹唑啉酮和6,2′,3′,4′,5′-取代的2,3-二氢-2-苯基-4-喹唑啉酮，并评价了它们对人肿瘤细胞系如鼻咽癌上皮细胞癌（KB）、肺癌（A-549）、回肠癌（HCT-8）、乳腺癌（MCF-7）、黑色素瘤（SKMEL-2）、卵巢癌（1A9）、胶质母细胞瘤（U-87-MG）、骨肉瘤（HOS）、表达P-gp的鼻咽癌上皮细胞癌（KB-VIN）和前列腺癌（PC3）细胞系的细胞毒性，发现其中一些化合物具有显著的活性。本发明还合成了2-苯基-4-烷氧基喹唑啉化合物，其中一些化合物显示出抗血小板活性。
• PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY
  申请人：Reborna Biosciences, Inc.

  公开号：EP3816160A1

  公开（公告）日：2021-05-05

  A prophylactic or therapeutic agent for spinal muscular atrophy according to the present invention includes a compound represented by the formula (I) or a salt thereof: wherein: W1, W2, and W3 are each independently selected from the group consisting of C-R2, C-R3, C-Rc, and C-Rd, and are defined by one of the followings (i) to (iv): (i) when W3 is C-R2, then W1 is C-R3, W2 is C-Rc or N, and R1 is a hydrogen atom; (ii) when W3 is C-R3, then W1 is C-R2, W2 is C-Rc or N, and R1 is a hydrogen atom, C1-8 alkyl, or C1-8 alkoxy; (iii) when W1 is C-R2, then W2 is C-Rc or N, W3 is C-Rd, and R1 is an aliphatic heterocycle containing one or more nitrogen atoms, the aliphatic heterocycle being optionally substituted with a non-aromatic substituent; and (iv) when W2 is C-R2, W1 is C-Rc, W3 is C-Rd, and R1 is an aliphatic heterocycle containing one or more nitrogen atoms, the aliphatic heterocycle being optionally substituted with a non-aromatic substituent; R2 is a 6- or more membered aromatic ring optionally substituted with a non-aromatic substituent; R3 is an aliphatic heterocycle containing one or more nitrogen atoms, the aliphatic heterocycle being optionally substituted with a non-aromatic substituent; Q1 is selected from C-Ra and N; Q2 is selected from C-Rb and N; and Ra, Rb, Rc, and Rd are each independently selected from the group consisting of a hydrogen atom, halogen, C1-8 alkyl, C1-8 alkoxy, and a cyano group.

  根据本发明，脊髓性肌萎缩症的预防或治疗剂包括由式（I）代表的化合物或其盐： 其中 W1、W2 和 W3 各自独立地选自由 C-R2、C-R3、C-Rc 和 C-Rd 组成的组，并由以下(i)至(iv)之一定义： (i) 当 W3 为 C-R2 时，W1 为 C-R3，W2 为 C-Rc 或 N，R1 为氢原子； (ii) 当 W3 为 C-R3 时，则 W1 为 C-R2，W2 为 C-Rc 或 N，且 R1 为氢原子、C1-8 烷基或 C1-8 烷氧基； (iii) 当 W1 是 C-R2，则 W2 是 C-Rc 或 N，W3 是 C-Rd，且 R1 是含有一个或多个氮原子的脂族杂环，该脂族杂环任选被非芳香族取代基取代；以及 (iv) 当 W2 为 C-R2、W1 为 C-Rc、W3 为 C-Rd 且 R1 为含有一个或多个氮原子的脂族杂环时，该脂族杂环可任选被非芳香族取代基取代； R2 是一个 6 个或多个成员的芳香环，可任选被一个非芳香族取代基取代； R3 是含有一个或多个氮原子的脂族杂环，该脂族杂环可选择被非芳香族取代基取代； Q1 选自 C-Ra 和 N； Q2 选自 C-Rb 和 N；以及 Ra、Rb、Rc 和 Rd 各自独立地选自由氢原子、卤素、C1-8 烷基、C1-8 烷氧基和氰基组成的组。
• PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION
  申请人：L'OREAL

  公开号：US20160143826A1

  公开（公告）日：2016-05-26

  The present invention relates to a process for dyeing human keratin fibres, in which use is made of one or more metal catalysts and a composition (A) comprising: (a) at least 10% by weight of one or more fatty substances, (b) one or more oxidation bases of formula (I) or (II), the addition salts thereof, solvates thereof and mixtures thereof: Formula (I), Formula (II) (c) one or more chemical oxidizing agents other than atmospheric oxygen. The invention also relates to a multi-compartment device and to a composition comprising all of the above-mentioned ingredients.
• US6479499B1
  申请人：——

  公开号：US6479499B1

  公开（公告）日：2002-11-12
• US9872822B2
  申请人：——

  公开号：US9872822B2

  公开（公告）日：2018-01-23